Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    Wavelength-Pharmaceuticals-Insert
    X

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Nuformix

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              CAMBODIA PHAR-MED 2020

              Participation Not Confirmed

              Update your events

              VistaGen and Nuformix agree to develop cocrystalline forms of AV-101

              Contact the Supplier

              Lead Product(s): 4-Chlorokynurenine,Probenecid

              Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: VistaGen Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement May 27, 2020

              Details:

              Under this agreement, VistaGen and Nuformix initially will apply Nuformix's proprietary technology platform to develop patentable new crystalline forms of AV-101 that may have superior delivery, an enhanced therapeutic profile and additional intellectual property protection.

              Eleusis

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              CAMBODIA PHAR-MED 2020

              Participation Not Confirmed

              Update your events

              Eleusis Announces Long Lasting Antidepressant-Like Effects of Psychedelics When Compared to Ketamine in Animals

              Contact the Supplier

              Lead Product(s): Psilocybine,Lysergide

              Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 05, 2020

              Details:

              The research reveals that both psilocybin and lysergic acid diethylamide (LSD) significantly reduce depressive-like behaviors five weeks after a single administration.

              PharmaCompass__DigitalAd